D-0095-2017 Class III Terminated

Recalled by Teva Pharmaceuticals USA — North Wales, PA

FDA drug recall D-0095-2017 was initiated by Teva Pharmaceuticals USA on Sep 13, 2016 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life. The recall status is terminated (terminated May 5, 2017). Affected quantity: 11,214 vials.

Recall details

Product Type
Drugs
Report Date
Oct 19, 2016
Initiation Date
Sep 13, 2016
Termination Date
May 5, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,214 vials

Product description

mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple Dose Vial, Rx only, Teva Parenteral Medicines, Inc., Irvine, CA 92618, NDC 0703-4685-01.

Reason for recall

Failed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.

Distribution pattern

Nationwide

Code information

Lot Numbers: 31318574B, Exp 09/16; 31319610B, Exp 07/17; 31320058B, Exp 11/17; 31320497B, Exp 12/17; 31320744B, Exp 02/18

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0095-2017
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0095-2017. Report a data issue: hello@regdatalab.com.